Introduction
Despite its decline in Western countries, gastric cancer remains the world's second leading cause of cancer mortality after lung cancer, accounting for approximately 12% of all cancer deaths [1, 2] . Radical surgery remains the only possibility of cure, though prognosis appears to be poor even for resected patients [3] ; indeed, the 5-year median overall survival for resected patients is about 30%. For this reason several trials, involving adjuvant and neoadjuvant treatments, are currently investigating the role of chemotherapy and radiotherapy [4] . Unfortunately, most patients relapse after surgery and many others are diagnosed when distant metastases are already present. For these patients only palliative chemotherapy can be offered.
In the 1990s three randomized trials of combination chemotherapy demonstrated benefi ts in terms of overall survival and quality of life in comparison with best supportive care [5] [6] [7] . The combination of 5-fl uorouracil (5-FU), doxorubicin, and mitomycin-C (FAM) was considered the standard regimen until the FAMTX schedule (including 5-FU, doxorubicin, high-dose methotrexate, and leucovorin) was shown to be superior in terms of both response rates (41% vs 9%) and overall survival (42 vs 29 weeks) [8] . On the other hand, cisplatin (CDDP)-based regimens demonstrated response rates of between 37% and 72% in phase II studies [9, 10] , although these results were not confi rmed in phase III studies [11] [12] [13] . More recently, the ECF combination regimen of CDDP, epirubicin (EPI), and infusional 5-FU proved very effective in phase II studies [14, 15] , and it was superior to FAMTX in terms of response rates (46% vs 21%; P = 0.0002) and overall survival (8.7 vs 6.1 months; P = 0.0005) in a randomized phase III comparison, with mild toxicity (16) . Since then the combination of CDDP and infusional 5-FU, with or without EPI, has become the most widely used regimen in front-line chemotherapy for advanced gastric cancer, even though some authors have reported no signifi cant differences between CDDP and non-CDDP-containing regimens [17, 18] . However, front-line chemotherapy for advanced gastric cancer has remained unsatisfactory, because overall survival does not generally exceed 10 months.
Great hope has been placed in new cytotoxic drugs, of which irinotecan (IRI), docetaxel (DTX), and loxaliplatin (OXA) seem the most promising. Both IRI and DTX have been shown to be active as fi rst-or second-line therapy in combination with CDDP or 5-FU in phase II studies [19] [20] [21] [22] [23] [24] . A triple combination of DTX with CDDP and 5-FU proved signifi cantly more effective than CDDP plus 5-FU, but overall survival was no more than 10.2 months, at the cost of higher toxicity [25] . On the other hand, the combination of IRI plus infusional 5-FU was superior to IRI plus CDDP in a randomized phase II study, and the combination was also shown to be no less effective than CDDP plus infusional 5-FU and to cause considerably less toxicity in a subsequent phase III trial [20, 21] .
Only a few studies of OXA in the treatment of advanced gastric cancer are available. In the wake of the satisfactory results achieved in colorectal cancer, it was widely used in combination with 5-FU (FOLFOX regimen), and was also found to show some activity in CDDP-pretreated patients [26] . As front-line chemotherapy in phase II studies, this combination yielded response rates and overall survival of up to 40% and 10 months, respectively [27] [28] [29] .
It has recently been shown that the combination of taxanes and OXA may be synergistic in vitro, when DTX is administered before OXA [30] ; the same conclusion was reached in a phase I study [31] . Based on these data, we decided to evaluate a regimen that combined OXA and DTX in pretreated patients with advanced gastric cancer.
Patients and methods
This mono-institutional phase II study was conducted in accordance with the updated Declaration of Helsinki and with the rules of the local Ethics Committee.
Patient selection
Patients with histologically proven recurrent, locally advanced, or metastatic adenocarcinoma of the stomach or of the esophageal-gastric junction, not suitable for resection, were included. The patients also were required to be between 18 and 75 years of age, with ECOG performance status of 2 or less, to present bidimensionally measurable lesions according to WHO criteria, and to have a life expectancy of more than 3 months. Documented progression after at least one previous chemotherapy cycle was also required, while prior radiotherapy on the target lesion was cause for exclusion from the study. Patients with local recurrence were acceptable if they had at least one measurable affected lymph node; cytological or histological confi rmation of metastasis was mandatory if only one metastatic lesion was present. All Exclusion criteria included: gastric or esophageal cancer other than adenocarcinoma; central nervous system metastases; unresolved bowel obstruction or sub-obstruction; chronic diarrhea; other serious medical conditions (unstable cardiac disease requiring treatment; uncontrolled angina pectoris; myocardial infarction within 6 months; active uncontrolled infections, uncontrolled diabetes with symptomatic peripheral neuropathy); any contraindication for DTX and OXA chemotherapy regimen; and history of other cancer, except for curatively treated nonmelanoma skin cancer or in-situ carcinoma of the cervix.
Treatment and study parameters
In the 2 days preceding the fi rst course of chemotherapy, and before each cycle, patients underwent a complete physical examination and laboratory tests, including blood count, serum chemistry, liver enzymes, urinalysis, and serum carcinoembryonic antigen (CEA). Blood count determination was repeated weekly. Baseline tumor assessment with prospective identifi cation of index lesion(s) was conducted not longer than 4 weeks before the enrollment and included abdomino-pelvic and lung computed tomography (CT) scans.
Chemotherapy consisted of: DTX 75 mg/m 2 on day 1 as a 60-min infusion and OXA 80 mg/m 2 on day 2 as a 3-h infusion. The day before starting chemotherapy patients received intramuscular dexamethasone 8 mg to prevent taxane-related allergic reactions; dexamethasone was continued every 12 h for 2 days after DTX. Routine antiemetic prophylaxis, also including a 5-hydroxytryptamine-3-receptor antagonist, was mandatory on day 1 and day 2. Treatment was repeated every 3 weeks.
Tumor response was assessed every three cycles by CT scan, according to WHO criteria. Chemotherapy was continued until disease progression, unacceptable toxicity, or the patient's refusal. In the case of disease progression, patients were treated with other drug combinations at the discretion of the investigators. Patients were considered evaluable for response if they had received a minimum of two cycles of the treatment. Patients who progressed before two cycles were also considered evaluable.
Clinical benefi t was assessed through a trial-specifi c pain checklist that was completed at baseline and every two cycles thereafter while patients were enrolled in the study; patients also recorded daily data on analgesic consumption and kept a weekly record of pain intensity on a 100-mm linear analog scale.
Toxicity assessment and management
Toxicity was assessed according to the National Cancer Institute (NCI) common toxicity criteria. Oxaliplatin (OXA)-related sensory neuropathy was scored as follows: grade 0, no toxicity; grade I, mild paresthesia, loss of deep tendon refl exes; grade II, moderate paresthesia and objective sensory loss (without functional impairment); grade III, functional impairment.
Chemotherapy was delayed until recovery if neutrophils decreased to less than 1.5 × 10 9 /l or platelets decreased to less than 100 × 10 9 /l or in case of mucositis or diarrhea greater than NCI grade I. Doses of DTX and OXA were reduced by 25% in case of NCI grade IV neutropenia, febrile neutropenia, NCI grade IV thrombocytopenia, NCI grade III-IV diarrhea and mucositis, or NCI grade IV nausea. In the case of grade II neuropathy, OXA was reduced by 25%, while in cases of grade III neuropathy it was discontinued. Secondary prophylaxis of neutropenia with colony-stimulating factors was allowed.
Statistical considerations
The primary endpoint was the overall response rate (complete plus partial response). Patients were recruited using a two-step phase II design according to Simon et al. [32] . If no objective response was observed in the fi rst 14 patients, a response rate greater than 15% could be excluded with 95% accuracy and recruitment would be discontinued. In the event of at least one partial response, more than 30 patients would need to be recruited to determine an accurate response rate.
Secondary endpoints were time to progression and overall survival. Time to progression was calculated from the start of chemotherapy to the date of progression, and survival was defi ned as the interval time between recruitment and death. The Kaplan-Meier method was used to analyze time to progression and survival. All data have been updated to April 2006. All patients had failed to respond to at least one previous chemotherapy regimen. First-line treatment was a combination regimen of CDDP, EPI, and 5-FU (ECF) for most patients (31; 81.5%); only 1 patient (2.6%) had received IRI plus 5-FU and the other 6 (15.7%) patients had been treated with a combination of CDDP and 5-FU (CF). Three of these 6 patients had disease progression 3-4 months after adjuvant chemotherapy with CDDP and 5-FU; for these patients, DTX and OXA was the fi rst-line treatment for advanced disease. Overall median time to progression after starting the fi rst-line treatment was 7.7 months (range, 2-17 months)
Results

Patients
Drug delivery and toxicity
A total of 164 cycles of DTX and OXA were administered to the 38 patients, with a median number of cycles administered per patient of 4.3 (range, 1-8). Dose reduction was required in 7 cycles (out of 164), but no delay in the start of chemotherapy was required.
Dose intensity of both OXA and DTX was 98.9%. The median cumulative dose of OXA was 344 mg/m 2 . The treatment was well tolerated and no toxic death occurred. The incidence of the main toxicities is summarized in Table 2 . The most common hematological side effect was neutropenia, though it was of grade 3-4 in only 10 patients (26.3%), while there were no recordings of febrile neutropenia, severe thrombocytopenia, or severe anemia. Eight patients (21.0%) and 2 patients (5.2%) experienced grade 2 anemia and grade 1-2 thrombocytopenia, respectively.
The most important nonhematological toxicities were grade 3 nausea/vomiting and grade 3 asthenia, both occurring in 6 patients (15.7%). When these two side effects were simultaneously present (2 patients) quality of life was signifi cantly affected, and a 25% dose reduction was introduced. The same combination of toxic effects caused 1 patient to refuse a dose reduction and to withdraw from the study. Grade 1-2 nausea was fairly frequent (20 patients; 52.6%), but was easily controlled with the appropriate antiemetic therapy. Grade 1-2 asthenia was also common (34.2% of patients). Gastrointestinal side effects other than nausea and vomiting were rare: 6 (15.7%) and 4 patients (10.5%) experienced grade 1-2 diarrhea and grade 1 stomatitis, respectively. Seven patients (18.4%) had grade 1-2 constipation after chemotherapy, probably because of the high dosage of 5-hydroxytryptamine-3-receptor antagonists as antiemetic medication. During chemotherapy 1 patient (2.6%) developed a deep venous thrombosis of the left leg.
Oxaliplatin (OXA)-related peripheral sensory neuropathy was a common side effect but it was generally mild, probably due to the low cumulative dose of OXA. Fourteen patients (36.8%) had grade 1 neuropathy and 2 patients (5.3%), grade 2 neurotoxicity. Only 1 patient experienced grade 3 neuropathy, after the sixth cycle of chemotherapy. No allergic reactions to OXA or DTX were recorded.
Effi cacy
All patients received at least one cycle of chemotherapy and 37 were assessable for response; 1 patient refused further treatment after the fi rst cycle of therapy. Evaluation of response, with 95% confi dence intervals (CI), is reported in Table 3 . No complete response was obtained; 4 patients had a confi rmed partial response, with an overall response rate of 10.5% (95% CI, 0.8-20.8). Eighteen patients experienced stabilization of the disease (47.3%; 95% CI, 32.5-64.8); the disease progressed in 15 patients (39.4%). Among patients with only peritoneal disease, stabilization was the best response in 3 of 5 patients. Seven of 18 the patients with stable disease experienced a clear clinical benefi t, with complete resolution of obstructive gastrointestinal symptoms (3 patients) and pain (3 patients) or resolution of hydronephrosis (1 patient). The median baseline serum CEA level in the 7 patients with stable disease and clinical benefi t (50.2 ± 41.4 ng/ml) remained unchanged or decreased after 3 and 6 months of treatment (27.5 ± 25.9 ng/ml and 17.4 ± 21.9 ng/ml, respectively; Fig. 1A ). In comparison, the median baseline serum CEA level (56.0 ± 70.3 ng/ml) in the other 11 patients with stable disease either remained unchanged or increased after 3 (65.3 ± 71.4 ng/ml) and 6 months (100.5 ± 106.5 ng/ml) of therapy, but in no patient was it decreased (Fig. 1B) . Median time to progression was 4.0 months (range, 2-8 months) and median overall survival was 8.1 months (range, 3-26 months), as reported in Figs. 2 and 3 , respectively.
Thirteen patients (34.2%) maintained a good performance status PS at the end of second-line treatment; 1 of these had recorded a PR; 5, SD; and 7, PD during DTX and OXA. They were given third-line chemotherapy with a regimen containing IRI plus continuous infusion 5-FU, as previously reported [20] . The median overall survival of patients receiving third-line chemotherapy was 16.3 months, while the remaining 25 patients recorded a median overall survival of 6.0 months (Fig. 4) ; this difference was statistically significant (P = 0.00099).
Discussion
Despite the large number of clinical trials and combination treatments evaluated, the chemotherapy of advanced gastric cancer remains unsatisfying. In phase III studies the median survival does not exceed 10 months, even with combination therapies including new drugs such as docetaxel (DTX) [11] [12] [13] 15, 16, 25] . These poor results are often obtained at the cost of a high incidence of hematological toxicity and diarrhea [25] . A possible strategy for improving the overall survival of patients with advanced gastric cancer could be an effective second-line therapy. A longer time to progression after second-line therapy might allow more patients to preserve a good performance status (PS) and receive further treatments. However, because the main therapeutic goal for most of these patients is palliation, second-line therapy has to be tolerable. We therefore studied a combination of DTX, which has established activity in advanced gastric cancer, and OXA, a platinum derivative whose adducts are not recognized by the mismatch repair (MMR) protein complex. In preliminary studies OXA yielded encouraging results in advanced gastric cancer in combination with infusional 5-FU, and was well tolerated [27] [28] [29] . Regimens and doses were selected on the basis of a previous phase I study in which this combination was investigated in patients affected by advanced breast or lung cancer [31] .
The most important result of our study is the high tolerability of the regimen, even though most patients had previously been treated with combination therapy including cisplatin (CDDP), and 50% of them had a PS of more than zero. No toxic death was observed, and the incidence of NCI-CTC grade 3-4 toxicity was very low. Only 26.3% of patients experienced NCI grade 3-4 neutropenia, with no febrile neutropenia or neutropenic infections. Hematological toxicity, other than neutropenia, was rare and never greater than grade 2. Among nonhematological toxicities, both grade 3 nausea/vomiting and grade 3 asthenia were experienced by 15.7% of patients and required a dose reduction in only two patients on account of their simultaneous occurrence. Oxaliplatin (OXA)-related sensory neuropathy was not an important concern; although mild neurotoxicity was common, only one patient experienced grade 3 cumulative neuropathy during the last course of chemotherapy, before progression was documented. The favorable toxicity profi le appears particularly advantageous in patients with advanced gastric cancer, whose quality of life can be severely affected by the superimposition of gastrointestinal side effects on the diseaserelated symptoms.
The activity of our regimen is comparable to that described for second-line DTX monotherapy or combination regimens, as reported mostly in non-CDDP pretreated patients [33] [34] [35] . Although a response rate of 10.5% is both low and lower than those reported in other phase II second-line studies with DTX or OXAcontaining regimens, a time to progression of 4.0 months is comparable to that reported in the same studies. This discrepancy might be related to the signifi cant and durable relief of symptoms in some patients with stable disease. Furthermore, more than 60% of patients in our study had peritoneal metastases, whose shrinkage according to WHO criteria is diffi cult to demonstrate. In effect, the simultaneous occurrence of relief of symptoms, a decrease in tumor markers, and stable disease cannot be unrelated to the action of chemotherapy, although it cannot be classifi ed as a partial response. In agreement with these considerations, the median overall survival time of 8.1 months was longer than expected for a second-line chemotherapy in advanced gastric cancer and is even comparable to that obtained in some front-line studies [11, 12, 15, 23, 26] . In our opinion, the median overall survival time achieved with our treatment could depend on the high level of tolerability of our treatment regimen, as well as on the possibility of third-line chemotherapy in a subset of patients. In fact, although only 34.2% of patients received further treatment with an IRI-containing regimen, their median survival reached 16.3 months. This could be the consequence of a selection of long survivors, but also suggests that sequential treatments are possible in advanced gastric cancer, provided they are tolerable and not crossresistant. In effect, the combination of IRI with infusional 5-FU has recently been demonstrated to be as effective as CDDP plus infusional 5-FU, but better tolerated [21] .
In conclusion, the combination of OXA and DTX is active to some extent as a second-line treatment of patients with advanced gastric cancer. The activity in a population of CDDP-pretreated patients is similar to that obtained with other DTX combinations in non-CDDP-pretreated patients. Interestingly, the combination of OXA and DTX is well tolerated and enables the administration of sequential treatments, which, in other gastrointestinal malignancies, have brought about a signifi cant prolongation of overall survival rates [36] [37] [38] . This fi nding does not exclude the need not only to optimize the combination of OXA and DTX but also to search for more active fi rst-line combinations and welltolerated sequences.
